Accelerate the development of your peptide therapeutic
Peptide drug products are a rapidly growing area within the pharmaceutical industry for oncology, metabolic disease, and rare and orphan indications.
However, the complexity and unique physicochemical properties of peptides present many challenges to drug developers.
With over 30 years of experience working on a variety of peptide programs across a range of delivery routes, we understand that there is no “one-size-fits-all” approach to formulation design.
We approach formulation development based on the physical, chemical, and biopharmaceutic properties of each peptide, with fit-for-purpose early development programs that meet Investigational New Drug Application (IND) and other regulatory requirements.
Our services span the entire drug development pathway, allowing us to support your program from candidate selection to commercial launch. Our scientists are skilled at developing strategies to reduce degradation and instability while maximizing absorption and bioavailability.
Get started today
Find out more about how Quotient Sciences can support your peptide development program. Download a copy of our featured case study and discuss your next program with us today.
Integrated strategies to accelerate peptide development
We leverage our flagship Translational Pharmaceutics® platform to integrate formulation development, real-time adaptive manufacturing, and clinical testing to accelerate your peptide development.
Flexible study protocols and rapid "make-test" cycles, all under one organization and a single program manager, enable formulation optimization in real-time based on arising clinical data to reduce development risks and maximize the probability of success.
Key applications include:
- Accelerating molecules from FIH to proof of concept (POC)
- Selecting and optimizing clinical formulations
- Optimizing formulations to minimize injection site reactions
- Managing route switches from parenteral to alternative routes such as oral delivery
Featured case study
Injectable route switch for peptide formulation optimization
Stealth BioTherapeutics developed an intravenous (IV) formulation of a peptide drug target and approached Quotient Sciences to develop a sub-cutaneous (SC) formulation to enable patient self-administration for a different indication. Learn how the Quotient Sciences Translational Pharmaceutics platform allowed a SC formulation that hit target parameters to be developed in less than 7 months.